Skip to main content

What Eli Lilly's Quarter ended Sep 30, 2026 10-Q says: 4 signals

Eli Lilly filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses acquisition completed, compliance burden and debt refinancing.

Public (LLY)Pharmaceutical Manufacturing10,000+ employeeslilly.comLinkedIn

Get Eli Lilly's live signals in Claude or ChatGPT, or by API

AskWhat changed at Eli Lilly this week? Use Autobound signals for lilly.com.
Filed
Oct 29, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
15

Source: Autobound Signal API · 114 signals tracked for Eli Lilly · updated

10-Q · latest 10

What Eli Lilly's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 4 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 7 signals

    SEC EDGAR

Earlier 10-Q filings

  • 10-Q · Quarter ended Mar 31, 2026Filed · 4 signalsSEC EDGAR

Showing 10 of 15 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Eli Lilly earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Full year 2026 revenue guidance raised to $91B-$92BFull year revenue outlook was raised to between $91 billion and $92 billion, driven by rapid uptake of the Medicare GLP-1 bridge program and robust international Mounjaro demand. Non-GAAP EPS expectations increased to $35 to $36, reflecting an operational increase of $4.07 per share at the midpoint prior to acquired IPR&D adjustments. The substantial top-line upgrade signals strong commercial...
Revenue grew 39% driven by Mounjaro and ZepboundWorldwide revenue increased nearly $7 billion or 39% compared to Q3 2025, driven by strong incretin volume and therapeutic area momentum. Gross margin expanded 80 basis points to 84.4%, while non-GAAP performance margin reached 54.2%. Strong revenue expansion provides significant budget flexibility for outward operational and commercial investments.
Broke ground on $11.5B manufacturing facilities in Texas and VirginiaThe company broke ground on two large-scale manufacturing facilities, comprising a $6.5 billion site in Houston, Texas, and a $5.0 billion site in Richmond, Virginia. These major capital commitments aim to support long-term production and global supply chain expansion for incretin products. Construction and automation rollouts create immediate procurement opportunities for engineering...
Completed acquisitions of AtaiBeckley and Merida BiosciencesThe company completed acquisitions of AtaiBeckley, adding neuroplasticens for mental health conditions, and Merida Biosciences, adding MR511 for precision immunology in Graves' disease. These business development transactions expand clinical pipelines across neuroscience and immunology. The onboarding of acquired clinical teams triggers standard vendor evaluations and laboratory informatics...
Launched Foundayo in UK, Mexico, Saudi Arabia and UAEInternational commercial rollout of oral obesity drug Foundayo advanced with launches in the UK, Saudi Arabia, Mexico, and the UAE, alongside preparations for 40 additional international markets in 2027. Expansion initially targets cash-pay and chronic weight management markets while reimbursement discussions progress. Geographic rollouts require localized distribution, compliance, and...
R&D spending increased 23% and SG&A rose 14%R&D expenses increased 23% in Q3 driven by clinical investments across early- and late-stage pipeline assets and newly acquired molecules. Marketing, selling, and administrative expenses rose 14% to support promotional and launch activities for current and upcoming products. Increased spending lines indicate active vendor engagement across clinical trial services and commercial sales software.

Signal API · MCP

Track Eli Lilly with the Signal API

One POST /v1/companies/enrich call with lilly.com returns Eli Lilly 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Eli Lilly 10-Q

When did Eli Lilly file its latest 10-Q?
Eli Lilly filed its latest 10-Q (Quarter ended Sep 30, 2026) on Oct 29, 2026. The one before it was filed on Aug 5, 2026.
What did Eli Lilly disclose in its latest 10-Q?
From the filing dated Oct 29, 2026: Eli Lilly issued $9.0 billion in long-term debt in May 2026
What did Eli Lilly say on its recent earnings calls?
Q3 FY2026: Full year 2026 revenue guidance raised to $91B-$92B (dated Oct 29, 2026).
Where can I read Eli Lilly's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/lly-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →